首页> 外文期刊>Clinical ophthalmology >Phakic Intraocular Lens Implantation After Deep Anterior Lamellar Keratoplasty: Retrospective Case Series Analysis With Long-Term Follow-Up
【24h】

Phakic Intraocular Lens Implantation After Deep Anterior Lamellar Keratoplasty: Retrospective Case Series Analysis With Long-Term Follow-Up

机译:深层前角膜层角膜移植术后晶状体人工晶状体植入:长期随访的回顾性病例系列分析。

获取原文
           

摘要

Purpose: To report outcomes of phakic intraocular lens (IOL) implantation after deep anterior lamellar keratoplasty (DALK) to correct high ametropia. Setting: Centro Hospitalar Universitário do Porto, Portugal. Methods: Retrospective case series with 11 eyes submitted to phakic IOL implantation after DALK. Main outcomes measured were uncorrected and corrected distance visual acuity (UDVA and CDVA), refractive error components, tomographic parameters and endothelial cell density (ECD). The minimum follow-up was 3 years for all cases. Results: Mean ECD loss was 8.7±6.7% at 1 year, 13.1±8.6% at 3 years (n=11; p=0.016, p=0.007, respectively) and 14.0±20.4% at 5 years (n=5, p=0.212). Mean logMAR UDVA increased from 1.27±0.90logMAR preoperatively to 0.16±0.15logMAR postoperatively ( p ≤0.001) and no statistically significant differences were registered during follow-up. All patients gained at least 5 lines of UDVA. 54.5% of the eyes gained 1 line in CDVA postoperative and only one eye lost one CDVA line through follow-up. Efficacy and safety indexes at 1 and 3 years were 1.01–0.97 and 1.24–1.21, respectively. Mean spherical equivalent was reduced from ?7.84±4.63 D preoperatively to ?1.05±1.07 D postoperatively ( p =0.001). Mean percentage of reduction in refractive cylinder and spherical error was 83.8±15.8% and 73.1±31.5%, respectively, p ≤0.001 for both. In one eye there was a significantly gradual ECD loss over 5 years follow-up and the patient will be submitted to IOL explant. Conclusion: Phakic IOLs were effective for correction high ametropia after DALK, showing high efficacy and safety indexes with stability over time. However, it was registered a continuing endothelial cell loss postoperatively, which assumed to be higher than those reported in eyes without DALK.
机译:目的:报告深前板层角膜移植术(DALK)矫正高度屈光不正后有晶状体人工晶状体(IOL)植入的结果。地点:葡萄牙波尔图大学中心医院。方法:回顾性病例系列,其中11只眼在DALK术后接受有晶状体人工晶体植入。测得的主要结局为未矫正和矫正的远视力(UDVA和CDVA),屈光不正分量,断层扫描参数和内皮细胞密度(ECD)。所有病例的最低随访时间为3年。结果:1年平均ECD损失为8.7±6.7%,3年平均nCD损失为13.1±8.6%(n = 11; p = 0.016,p = 0.007)和5年平均为14.0±20.4%(n = 5,p = 0.212)。 logMAR UDVA平均数从术前的1.27±0.90logMAR增加到术后的0.16±0.15logMAR(p≤0.001),且随访期间无统计学差异。所有患者均获得至少5行UDVA。术后有54.5%的眼睛在CDVA中获得1条线,只有一只眼睛在随访中失去了一条CDVA线。 1年和3年的有效性和安全性指数分别为1.01-0.97和1.24-1.21。平均球当量从术前的?7.84±4.63 D降低到术后的?1.05±1.07 D(p = 0.001)。屈光柱体的平均减少百分比和球面误差分别为83.8±15.8%和73.1±31.5%,两者均p≤0.001。一只眼睛在5年的随访中有明显的逐渐ECD丧失,该患者将接受IOL外植体治疗。结论:晶状体人工晶状体可有效纠正DALK后的高度屈光不正,显示出高疗效和安全性指标,并具有长期稳定性。然而,它被记录为术后持续的内皮细胞丢失,这被认为高于没有DALK的眼睛中报道的那些。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号